New combo tackles tough pancreatic cancer resistance
NCT ID NCT05518110
First seen Apr 19, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. It included 20 adults whose cancer had not responded to at least one prior therapy. The goal was to see if the combination could slow or stop cancer growth, but the study was ended early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mater Misericordiae University Hospital
Dublin, D07 R2WY, Ireland
-
St Vincent's University Hospital
Dublin, DO4 T6F4, Ireland
Conditions
Explore the condition pages connected to this study.